Introduction
The α 1 -adrenergic receptors (α 1 -AR) play a key role in the modulation of sympathetic nervous system activity as well as a site of action for therapeutic agents, such as antihypertensive drugs. Three subtypes of the α 1 -AR, α 1A -AR, α 1B -AR, and α 1D -AR have been cloned and each has specific tissue distribution and pharmacological properties [1, 2] . All subtypes of the α 1 -AR are Gq protein-coupled receptors, which upon activation, catalyze the cleavage of polyphosphoinositide into dual signaling molecules, inositol 1,4, 5-trisphosphate (IP 3 ), and diacylglycerol via the activation of phospholipase C. IP 3 leads to the opening of IP 3 receptor channels at the endoplasmic/sarcoplasmic reticulum, and subsequently the release of intracellular Ca 2+ , while the activation of protein kinase C is the downstream signaling pathway for diacylglycerol [3, 4] . Through these signal transduction pathways, the intracellular responses upon α 1 -AR stimulation are induced.
Accumulating studies have indicated that the α 1 -AR system appears to play a role in cardiac growth, cardiac contraction, and cardiac automaticity in physiological condition [4] [5] [6] , as well as in cardiac pathological processes, such as arrhythmogenesis or cardiac adaptation to various situations [5, 7, 8] .
signaling, a common event seen in α 1 -AR stimulation, is considered to be a primary signaling pathway initiating acute as well as chronic cardiac function modulations by the α 1 -AR [2, [7] [8] [9] [10] [11] . For instance, the α 1 -AR-mediated mobilization of Ca 2+ from the sarcoplasmic reticulum contributes significantly to excitation-contraction coupling in atrial myocytes, and causes arrhythmogenic intracellular Ca 2+ oscillations in the ischemic heart [7, 9, 10] . Additionally, α 1 -AR-mediated Ca 2+ signaling is essential for the activation of calmodulin-dependent protein kinase II and nuclear factor of activated T cells, both of which signal a hypertrophic program of cardiac gene expression [8, 12, 13] . All 3 subtypes of α 1 -AR have been detected at the levels of messenger RNA as well as protein in the heart [14, 15] . How-ever, the subtype of the receptor in the mediation of cardiac function is not clear. Many studies have suggested that the α 1A -AR and α 1B -AR appear to play major roles in the heart [3, 6, 15, 16] . More recently however, the α 1A -AR has been demonstrated to sufficiently induce cardiac arrhythmias and hypertrophy, while the α 1B -AR seems less important [7, 17, 18] . Furthermore, the avtivation of α 1B -AR even inhibits α 1A -AR mediated cardiac remodeling [19] , but plays a crucial role in the generation of dilated cardiomyopathy [16] . As an increase in intracellular Ca 2+ is the primary signaling transduction pathway for α 1 -AR-mediated cardiac function [2, [7] [8] [9] [10] [11] , and the subtype involved is unclear, in this study we intended to identify the subtype of the α 1 -AR involved in mediating intracellular Ca 2+ signaling by using neonatal rat ventricular myocytes (NRVM), which express all 3 α 1 -AR subtypes [14, 15] and respond to α 1 -AR stimulation markedly in the profiles of intracellular Ca 2+ signaling and hypertrophic growth [8, 20, 21] .
Material and methods
Isolation and culture of cardiomyocytes NRVM were isolated from 1-2-d-old Sprague-Dawley rats by enzymatic digestion with 0.1% trypsin and 0.03% collegenase, as previously described [20] . Then the myocytes were plated onto laminin-coated, 35 mm dishes at a density of 0.5×10 3 -0.8×10 3 cells/mm 2 and cultured for 42 h in Dulbecco's modified Eagle's medium (DMEM) and Medium 199 (4:1) containing 10% fetal bovine serum, 4 mmol/L L-glutamine, 100 units/ mL penicillin/streptomycin, and 0.1 mmol/L 5-bromo-2-deoxyuridine to inhibit fibroblast proliferation. Before use, the myocytes were further cultured for 6 h in serum-free DMEM to eliminate any influence of some factors in the serum. Materials 5-Bromo-2-deoxyuridine, phenylephrine, 5- [4, 5] decane-7,9-dione dihydrochloride}, propranolol, and prazosin were purchased from Sigma-Aldrich (St Louis, MO, 
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methylurapidil (5-Mu), chloroethylclonidine (CEC), BMY 7378 {8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiroUSA). A61603 {N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2- hydroxy-5,
Results
In fluo-4-loaded NRVM, due to spontaneous action potentials as the trigger, rhythmic and spontaneous Ca 2+ oscillations, were observed at a rate of 6.02±0.58 min -1 (n=12 experiments). Phenylephrine (PE, 10 µmol/L), a non-subtype specific agonist of the α 1 -AR [17, 19, 22] , increases the frequency of the spontaneous Ca 2+ transients ( Figure 1A , upper panel), which was completely blocked with 1 µmol/L prazosin, an α 1 -AR antagonist, but not the β-AR antagonist propranolol at 1 µmol/L. This effect of PE is dose-dependent with an EC 50 value (the concentration for inducing 50% of maximal response) of 2.3 µmol/L ( Figure 1B) . To determine the role of the α 1 -AR subtypes in [Ca 2+ ] i regulation, we then examined the effects of subtype-specific antagonists on PEmediated Ca 2+ signal. As shown in Figure 1 (1A, bottom panel, 1C), pretreatment of myocytes with 5-Mu for 10 min, a specific inhibitor of the α 1A -AR [23] , caused dose-dependent suppression of the stimulatory response to PE (10 µmol/L) with an IC 50 value (the concentration for 50% inhibition of agonist-induced response) of 6.7 nmol/L, and a complete abolishment was seen at a concentration of 30 nmol/L. In contrast, pretreatment of the cells for 30 min with CEC to inhibit the α 1B -AR showed no influence, except that CEC at higher concentration (30 µmol/L) induced a 33.5% inhibition of PE-enhanced Ca 2+ transients ( Figure 1D ). The alkylating agent CEC primarily inactivates the α 1B -AR, but studies have shown that this compound can also produce partial inactivation of the other subtypes, especially α 1A -AR, with prolonged exposure at high concentrations [24, 25] . Thus, the partial blockade of the PE effect by CEC at higher concentration is most likely due to its non-specific inhibition of other subtypes.
Nevertheless, blockade of the α 1D -AR with BMY 7378 (0.1 µmol/L) [26, 27] demonstrated no any influence in the PE effect ( Figure 1D) . Presently, the α 1D -AR expressing much less than other subtypes in cardiomyocytes is functionally unknown in the heart [3, 15] . These findings provide clues that the α 1A -AR, not the α 1B -AR and α 1D -AR, may be the primary mediator of PE-regulated spontaneous Ca 2+ transients. At present, the determination of the role of the α 1A -AR versus the α 1B -AR subtypes in mediating physiological responses to α 1 -adrenergic stimulation is difficult because of the paucity of highly selective antagonists specific for one subtype over the other. Therefore, to further discriminate the α 1A -AR from other subtypes, we investigated subtype specific agonists in this protocol. So far no specific com- pound for the α 1B -AR or the α 1D -AR subtype is available, so we examined the effects of A61603, the recently described potent α 1A -adrenergic agonist [28] , and compared the doseresponse characteristics of PE and A61603. As shown in Figure 2 (2A,2C), A61603 induced a dose-response increase in spontaneous Ca 2+ transients with an EC 50 value of 6.9 nmol/L, indicating a 330-fold greater potency for PE (2.3 µmol/L). Furthermore, we tried to find the concentration of A61603 at which stimulated Ca 2+ transients with a similar potency to that of PE so as to evaluate and compare the inhibitory effect of 5-Mu. We observed that 30 nmol/L A61603 potentiated the rate of Ca 2+ transients with an almost same potency as that of 10 µmol/L PE (2.11 and 2.09 times that of the control, respectively; Figure 2C ,2D). Similar as its effect on PE ( Figure  1D ), 5-Mu (30 nmol/L), pretreatment of cells for 10 min, abolished the increment in Ca 2+ transients induced by 30 nmol/L A61603 ( Figure 2B,2D) , while no effect was observed in 10 µmol/L CEC-or 0.1 µmol/L BMY 7378-treated cells (data not shown).
As spatial temporal Ca 2+ sparks or waves constitute the elementary events of Ca 2+ signaling in response to α 1 -adrenergic stimulation inside the cells, we then investigated the characteristics of Ca 2+ sparks mediated by PE and A61603 in NRVM. With the aid of the line-scan confocal imaging of NRVM ( Figure 3A , inset), we found that Ca 2+ sparks occurred at a frequency of 1.56±0.2/100 µm·s or 1.27±0.15/100 µm·s in the control condition (in the absence of PE or A61603, respectively). PE (10 µmol/L) and A61603 (30 nmol/L) elicited a spark increase by 2.0-and 2.3-fold, respectively ( Figure  3A, 3B) , while the amplitude, width, and duration of the Ca 2+ sparks were not altered by either treatment of the agonists. Consistent with the data in global Ca 2+ transients, the local Ca 2+ release responses to PE and A61603 could be abolished by 30 nmol/L 5-Mu ( Figure 3B, 3C) , but not by 10 µmol/L CEC or 0.1 µmol/L BMY 7378 treatment (data not shown). Therefore, the similar responses to A61603 and PE from local Ca 2+ release to global Ca 2+ transients, and a complete abolishment of both effects by specific α 1A -AR antagonist, strongly suggest that the α 1A -AR subtype plays a major role in the α 1 -AR-associated regulation of intracellular Ca 2+ signaling in NRVM.
Discussion

Increases in intracellular Ca
2+ signaling have been implicated to be an essential signal transduction event in the regulation of cardiac functions by α 1 -AR stimulation [2, [7] [8] [9] [10] [11] 20, 21] . However, the subtype involved is not clear. The present study demonstrates that the stimulatory responses of spontaneous Ca 2+ oscillations to α 1 -AR activation were greatly sensitive to and selectively abolished by the α 1A -AR antagonist, but not by antagonism of the α 1B -AR or the α 1D -AR subtype (Figure 1) . Additionally, A61603, the novel α 1A -AR-selective agonist, exhibited a 330-fold greater potency than PE in stimulating spontaneous Ca 2+ transient activity ( Figure 2 ). This is in agreement with the findings that A61603 produces 340-and 330-fold greater potency than PE in stimulating sarcolemmal Na-H exchange activity in rat ventricular myocytes and in inducing contraction of the rat vas deferens, respectively. These physiological activities of α 1 -AR activation are further confirmed to be mediated by α 1A -AR selectively [22, 28] . Furthermore, Ca 2+ sparks, an important event of the local Ca 2+ releasing activity, were also stimulated by PE and A61603 with almost an equal potency with that in stimulating Ca 2+ transients. This response to PE or A61603 is consistently abolished by the α 1A -AR antagonist, but not by α 1B -AR or α 1D -AR inhibition (Figure 3 ). Taking these results together, these observations provide supportive evidence that α 1 -adrenergic stimulation of Ca 2+ signaling activity is mediated selectively by the α 1A -AR subtype. Our previous study and those of others have shown that stimulated intracellular Ca 2+ signaling plays an important role in the induction and perpetuation of cardiac hypertrophy by α 1 -AR activation [11, 12, 20, 21] . Importantly, studies have shown that the α 1A -AR subtype is sufficient in inducing hypertrophy in cultured cardiac myocytes [17, 18] and is important in the development of the heart [6] . Thus, combined with the previous reports, the present study suggests that α 1A -AR-mediated Ca 2+ signaling response may assume greater significance in hypertrophy formation. Additionally, Ca 2+ signal abnormity has also been suggested to play a key role in triggering ectopic automaticity in physiological as well as pathological circumstances, such as cardiac ischemia and heart failure [7, 9, 10] and α 1 -AR activation appears to be one of the important underlying mechanisms in this regard [7, [29] [30] [31] . Interestingly, the α 1A -AR has been suggested to be the crucial arrhythmogenic subtype by both in vivo and in vitro studies [7, 9] . Therefore, taken these results together, the finding that the α 1A -AR is the major subtype in intracellular Ca 2+ signaling regulation during α 1 -AR activation may provide significant information for the functional roles of the α 1 -AR subtype and an alternate insight into the potential therapeutic candidates in heart remodeling and arrhythmias, particularly in humans as the α 1A -AR appears to be the predominant subtype expressed in the human ventricular myocardium [32] . In summary, the present study has shown that the α 1A -AR is the predominant subtype in regulating intracellular Ca 2+ signaling for the α 1 -AR activation of neonatal rat ventricular myocytes, which may provide potential information for more specific drug development to hinder the cardiac remodeling process.
